CN1660108A - 高度选择性去甲肾上腺素再摄取抑制剂及其用途 - Google Patents

高度选择性去甲肾上腺素再摄取抑制剂及其用途 Download PDF

Info

Publication number
CN1660108A
CN1660108A CN2004101045222A CN200410104522A CN1660108A CN 1660108 A CN1660108 A CN 1660108A CN 2004101045222 A CN2004101045222 A CN 2004101045222A CN 200410104522 A CN200410104522 A CN 200410104522A CN 1660108 A CN1660108 A CN 1660108A
Authority
CN
China
Prior art keywords
reboxetine
disorder
norepinephrine
disorders
reuptake
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2004101045222A
Other languages
English (en)
Chinese (zh)
Inventor
E·H·F·翁
S·阿莫德
R·C·马歇尔
R·麦克阿瑟
D·P·泰勒
L·伯格森
P·塞特拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1660108(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of CN1660108A publication Critical patent/CN1660108A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2004101045222A 1999-07-01 2000-06-22 高度选择性去甲肾上腺素再摄取抑制剂及其用途 Pending CN1660108A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US14196899P 1999-07-01 1999-07-01
US60/141,968 1999-07-01
US14413199P 1999-07-16 1999-07-16
US60/144,131 1999-07-16
US15825699P 1999-10-06 1999-10-06
US60/158,256 1999-10-06
US17038199P 1999-12-13 1999-12-13
US60/170,381 1999-12-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB008084858A Division CN1205935C (zh) 1999-07-01 2000-06-22 高度选择性去甲肾上腺素再摄取抑制剂及其使用方法

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN 200510136906 Division CN1820754A (zh) 1999-07-01 2000-06-22 高度选择性去甲肾上腺素再摄取抑制剂及其用途
CN 200610099898 Division CN1969859A (zh) 1999-07-01 2000-06-22 高度选择性去甲肾上腺素再摄取抑制剂及其用途

Publications (1)

Publication Number Publication Date
CN1660108A true CN1660108A (zh) 2005-08-31

Family

ID=27495506

Family Applications (5)

Application Number Title Priority Date Filing Date
CN2004101045241A Pending CN1660110A (zh) 1999-07-01 2000-06-22 高度选择性去甲肾上腺素再摄取抑制剂及其用途
CN2004101045222A Pending CN1660108A (zh) 1999-07-01 2000-06-22 高度选择性去甲肾上腺素再摄取抑制剂及其用途
CN2004101045237A Pending CN1660109A (zh) 1999-07-01 2000-06-22 高度选择性去甲肾上腺素再摄取抑制剂及其用途
CNB008084858A Expired - Fee Related CN1205935C (zh) 1999-07-01 2000-06-22 高度选择性去甲肾上腺素再摄取抑制剂及其使用方法
CNB2004101045256A Expired - Fee Related CN1289090C (zh) 1999-07-01 2000-06-22 高度选择性去甲肾上腺素再摄取抑制剂及其在制备药物方面的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2004101045241A Pending CN1660110A (zh) 1999-07-01 2000-06-22 高度选择性去甲肾上腺素再摄取抑制剂及其用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN2004101045237A Pending CN1660109A (zh) 1999-07-01 2000-06-22 高度选择性去甲肾上腺素再摄取抑制剂及其用途
CNB008084858A Expired - Fee Related CN1205935C (zh) 1999-07-01 2000-06-22 高度选择性去甲肾上腺素再摄取抑制剂及其使用方法
CNB2004101045256A Expired - Fee Related CN1289090C (zh) 1999-07-01 2000-06-22 高度选择性去甲肾上腺素再摄取抑制剂及其在制备药物方面的用途

Country Status (30)

Country Link
US (18) US6465458B1 (enExample)
EP (3) EP2087892A3 (enExample)
JP (3) JP2003503450A (enExample)
KR (5) KR100717660B1 (enExample)
CN (5) CN1660110A (enExample)
AR (1) AR035158A1 (enExample)
AT (9) ATE305307T1 (enExample)
AU (2) AU771258B2 (enExample)
BR (1) BR0012136A (enExample)
CA (2) CA2643231A1 (enExample)
CL (3) CL2008002868A1 (enExample)
CO (1) CO5190662A1 (enExample)
CZ (1) CZ299847B6 (enExample)
DE (9) DE60019473T2 (enExample)
DK (4) DK1632234T3 (enExample)
EA (6) EA011094B1 (enExample)
ES (9) ES2258010T3 (enExample)
GE (1) GEP20094798B (enExample)
HU (1) HUP0201623A3 (enExample)
IL (3) IL147246A0 (enExample)
MX (1) MXPA02000562A (enExample)
MY (1) MY137348A (enExample)
NO (4) NO20016406L (enExample)
NZ (2) NZ533243A (enExample)
PE (1) PE20010684A1 (enExample)
PL (1) PL196996B1 (enExample)
PT (5) PT1196172E (enExample)
SK (5) SK286864B6 (enExample)
TW (9) TWI298255B (enExample)
WO (1) WO2001001973A2 (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA011094B1 (ru) * 1999-07-01 2008-12-30 Фармация Энд Апджон Компани Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
EP1600168A3 (en) * 1999-12-01 2009-09-23 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder
AU5311401A (en) 2000-04-21 2001-11-07 Upjohn Co Compounds for treating fibromyalgia and chronic fatigue syndrome
HK1054190A1 (zh) * 2000-04-21 2003-11-21 法玛西雅厄普约翰美国公司 用於治疗肌纤维疼痛和慢性疲劳综合征的精选化合物
WO2002036125A1 (en) * 2000-10-31 2002-05-10 Head Explorer A/S The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
AU2002217757A1 (en) * 2000-11-15 2002-05-27 Eli Lilly And Company Treatment of anxiety disorders
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
EA009780B1 (ru) * 2001-06-19 2008-04-28 Норберт Мюллер Применение ингибиторов cox-2 для лечения шизофрении, аффективных расстройств или осложнений, связанных с тиком
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
CA2466649A1 (en) * 2001-11-30 2003-06-12 Eli Lilly & Company Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
IL161989A0 (en) * 2001-12-11 2005-11-20 Lilly Co Eli Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
AU2003213009A1 (en) * 2002-02-12 2003-09-04 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
JP4545584B2 (ja) * 2002-05-17 2010-09-15 デューク ユニバーシティ 肥満を治療するための方法
AU2003227520B9 (en) * 2002-05-30 2008-06-26 Neurosearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
KR100779786B1 (ko) * 2002-06-17 2007-11-28 화이자 이탈리아 에스.알.엘. 레복세틴의 제약 염
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
MXPA05001705A (es) * 2002-08-14 2005-04-19 Pharmacia & Upjohn Co Llc Uso de reboxetina para el tratamiento de sofocos.
ATE327982T1 (de) 2002-08-23 2006-06-15 Lilly Co Eli Benzylmorpholinderivate
US7384941B2 (en) 2002-08-23 2008-06-10 Eli Lilly And Company 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
AU2003284005B2 (en) * 2002-10-03 2009-12-17 Forest Laboratories Holdings Limited Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
PL378369A1 (pl) * 2003-01-13 2006-04-03 Dynogen Pharmaceuticals, Inc. Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji
AU2004204825B2 (en) * 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
AU2004227945B2 (en) * 2003-04-04 2006-10-26 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
MXPA05011557A (es) 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
GB0319793D0 (en) 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
WO2005020976A2 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
CA2537402C (en) * 2003-09-12 2009-05-05 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7550485B2 (en) 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
CA2548304A1 (en) * 2003-12-12 2005-07-07 Eli Lilly And Company Selective norepinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
DE602004019698D1 (de) 2003-12-23 2009-04-09 Lilly Co Eli Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
GEP20084550B (en) * 2004-04-30 2008-11-25 Warner Lambert Co Substituted morpholine compounds for the treatment of central nervous system disorders
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
KR100871272B1 (ko) * 2004-04-30 2008-11-28 화이자 인코포레이티드 모폴린 화합물
US20080261984A1 (en) * 2004-06-09 2008-10-23 Pfizer Inc. Use of S,S-Reboxetine in the Treatment of Pain
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20090227562A1 (en) * 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
EP2286801A3 (en) 2004-08-13 2012-05-09 Boehringer Ingelheim International GmbH Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
JP2008514689A (ja) * 2004-10-01 2008-05-08 ニューロキュア リミテッド Ａｄｈｄ、ｃｆｓ、ｆｍおよび鬱病の処置のためのロフェプラミンの薬学的な組成物の使用
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
EP2292220A3 (en) 2005-11-22 2012-01-04 Orexigen Therapeutics, Inc. Composition and methods for increasing insulin sensitivity
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
DK1948155T3 (da) * 2006-06-28 2012-07-02 Chelsea Therapeutics Inc Farmaceutiske præparater omfattende droxidopa
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
BRPI0808647A2 (pt) 2007-03-09 2014-08-12 Chelsea Therapeutics Inc Método para tratar a síndrome de sensibilidade central, método para reduzir, eliminar ou prevenir a dor associada à fibromialgia, kit útil para o tratamento de uma síndrome de sensibilidade central.
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
AU2008245836A1 (en) * 2007-04-30 2008-11-06 Adolor Corporation Compositions of (-)-E-10-OH-NT and methods for their synthesis and use
ES2431570T3 (es) * 2007-05-07 2013-11-27 Chelsea Therapeutics, Inc. Droxidopa y composición farmacéutica de la misma para el tratamiento de los trastornos por déficit de atención
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20090233959A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US20090233957A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation (-)-beloxepin and methods for its synthesis and use
US8475823B2 (en) 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
WO2010011811A2 (en) * 2008-07-24 2010-01-28 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2010044016A1 (en) * 2008-10-17 2010-04-22 Pfizer Limited Novel uses for esreboxetine and racemic reboxetine
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
WO2011008666A2 (en) 2009-07-13 2011-01-20 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
US8273786B2 (en) * 2009-07-21 2012-09-25 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
CA2811641A1 (en) 2010-10-11 2012-04-19 Theravance, Inc. Serotonin reuptake inhibitors
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
KR20220042241A (ko) 2012-06-06 2022-04-04 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
WO2016077724A1 (en) 2014-11-13 2016-05-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education (2-amino-4(arylamino)phenyl) carbamates
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
EP3693020A1 (en) * 2019-02-08 2020-08-12 Burmaster International Group GmbH Potassium enriched topical formulations for pain relief and sleep aid
BR112022010677A2 (pt) * 2019-12-03 2022-08-16 Axsome Therapeutics Inc Uso de reboxetina para tratar transtornos do sistema nervoso

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4465458A (en) * 1980-03-19 1984-08-14 Matsushita Electric Industrial Co., Ltd. Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US4596807A (en) 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
AU642582B2 (en) 1991-02-25 1993-10-21 Eli Lilly And Company Treatment of lower urinary tract disorders
US5281624A (en) 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
IL111786A0 (en) 1993-12-01 1995-01-24 Max Planck Gesellschaft Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
WO1997035584A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
AU725556B2 (en) 1996-03-25 2000-10-12 Eli Lilly And Company Method for treating pain
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
US6572880B2 (en) * 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
WO1999011208A1 (en) 1997-08-28 1999-03-11 Williams C Donald Method and composition for transdermal administration of pharmacologic agents
US6479074B2 (en) * 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
DE59600683D1 (de) 1996-11-27 1998-11-19 Pfleger R Chem Fab Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
AU6966998A (en) 1997-04-11 1998-11-11 Eli Lilly And Company Composition for treating pain
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
UA57107C2 (uk) 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
AU9214498A (en) * 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
AU9692898A (en) 1997-10-17 1999-05-10 Eli Lilly And Company Potentiation of pharmaceuticals
CA2321157A1 (en) * 1998-04-09 1999-10-21 Pharmacia & Upjohn Company New treatments for nervous disorders
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
IT1305322B1 (it) 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
JP2002514601A (ja) * 1998-05-08 2002-05-21 ファルマシア・アンド・アップジョン・カンパニー Ｎ．ａ．ｒ．ｉ．、好ましくはレボキセチンおよびピンドロールの新しい薬物組合せ
HUP0102728A3 (en) 1998-06-29 2002-12-28 Pharmaceuticals Applic Associa Methods and transdermal compositions for pain relief
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
EA011094B1 (ru) * 1999-07-01 2008-12-30 Фармация Энд Апджон Компани Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
WO2001062236A2 (en) 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

Also Published As

Publication number Publication date
ES2246487T3 (es) 2006-02-16
EA011094B1 (ru) 2008-12-30
JP2006143749A (ja) 2006-06-08
SK286669B6 (sk) 2009-03-05
HUP0201623A3 (en) 2004-12-28
TW200607509A (en) 2006-03-01
PE20010684A1 (es) 2001-06-24
CA2375908C (en) 2006-05-30
NO20016406D0 (no) 2001-12-28
CZ20014625A3 (cs) 2002-08-14
PL352252A1 (en) 2003-08-11
ATE305307T1 (de) 2005-10-15
PT1196172E (pt) 2006-05-31
US7276503B2 (en) 2007-10-02
CN1660110A (zh) 2005-08-31
TW200607512A (en) 2006-03-01
PT1459748E (pt) 2005-08-31
TW200922594A (en) 2009-06-01
US6610690B2 (en) 2003-08-26
US6987107B2 (en) 2006-01-17
ATE304358T1 (de) 2005-09-15
ES2239311T3 (es) 2005-09-16
KR100704319B1 (ko) 2007-04-09
PT1459750E (pt) 2005-08-31
CN1289090C (zh) 2006-12-13
NO20091168L (no) 2002-02-19
ES2258010T3 (es) 2006-08-16
TW200914027A (en) 2009-04-01
EP1196172B1 (en) 2006-03-15
US20090247528A1 (en) 2009-10-01
EP2087892A2 (en) 2009-08-12
HUP0201623A2 (en) 2002-09-28
US20080103147A1 (en) 2008-05-01
US20060135520A1 (en) 2006-06-22
PL196996B1 (pl) 2008-02-29
WO2001001973A3 (en) 2002-01-17
EA006652B1 (ru) 2006-02-24
CL2008002866A1 (es) 2009-01-09
WO2001001973A2 (en) 2001-01-11
DK1459750T3 (da) 2005-08-15
ES2246488T3 (es) 2006-02-16
US20080096890A1 (en) 2008-04-24
US20060264436A1 (en) 2006-11-23
MXPA02000562A (es) 2002-07-02
NO20091159L (no) 2002-02-19
SK286668B6 (sk) 2009-03-05
NZ515885A (en) 2004-08-27
DE60020613D1 (de) 2005-07-07
TWI294779B (en) 2008-03-21
EA200700232A1 (ru) 2007-06-29
EP1196172A2 (en) 2002-04-17
TWI298254B (en) 2008-07-01
US7317011B2 (en) 2008-01-08
KR100717660B1 (ko) 2007-05-15
ATE296634T1 (de) 2005-06-15
JP2006321815A (ja) 2006-11-30
NO20091158L (no) 2002-02-19
US6703389B2 (en) 2004-03-09
DK1632234T3 (da) 2007-09-17
DE60020613T2 (de) 2006-03-16
KR20090087134A (ko) 2009-08-14
DE60035232T2 (de) 2008-02-14
ATE305306T1 (de) 2005-10-15
TW200920378A (en) 2009-05-16
AR035158A1 (es) 2004-05-05
US20060135521A1 (en) 2006-06-22
EA200200111A1 (ru) 2002-06-27
DE60022916T2 (de) 2006-07-06
AU5633700A (en) 2001-01-22
US7723334B2 (en) 2010-05-25
CN1379672A (zh) 2002-11-13
DE60022917D1 (de) 2006-02-09
CZ299847B6 (cs) 2008-12-10
CN1660109A (zh) 2005-08-31
DK1459749T3 (da) 2006-01-09
ES2247572T3 (es) 2006-03-01
TWI245631B (en) 2005-12-21
US7338953B2 (en) 2008-03-04
EA005029B1 (ru) 2004-10-28
US20020061910A1 (en) 2002-05-23
EP2087892A3 (en) 2009-09-30
ATE305788T1 (de) 2005-10-15
KR20060099544A (ko) 2006-09-19
US20080103146A1 (en) 2008-05-01
CN1660111A (zh) 2005-08-31
US20040147614A1 (en) 2004-07-29
US20060128705A1 (en) 2006-06-15
TWI298255B (en) 2008-07-01
ATE319453T1 (de) 2006-03-15
NZ533243A (en) 2005-12-23
EA200501496A1 (ru) 2006-06-30
DE60022692D1 (de) 2005-10-20
AU2004202096B2 (en) 2005-10-20
KR100935277B1 (ko) 2010-01-06
CN1205935C (zh) 2005-06-15
ATE364386T1 (de) 2007-07-15
CO5190662A1 (es) 2002-08-29
TWI293250B (en) 2008-02-11
CA2643231A1 (en) 2001-01-11
KR20050053799A (ko) 2005-06-08
DE60022916D1 (de) 2006-02-09
ATE320257T1 (de) 2006-04-15
US7241762B2 (en) 2007-07-10
MY137348A (en) 2009-01-30
US6642235B2 (en) 2003-11-04
EP2090312A1 (en) 2009-08-19
DE60023043D1 (de) 2006-02-16
IL147246A0 (en) 2002-08-14
DE60026704T2 (de) 2006-10-19
EA008381B1 (ru) 2007-04-27
IL187512A0 (en) 2008-06-05
ES2285645T3 (es) 2007-11-16
CL2008002867A1 (es) 2009-01-09
ES2246485T3 (es) 2006-02-16
DE60023043T2 (de) 2006-06-14
ATE292971T1 (de) 2005-04-15
WO2001001973A8 (en) 2001-05-17
ES2242175T3 (es) 2005-11-01
DE60022917T2 (de) 2006-06-29
DE60026627D1 (de) 2006-05-04
DK1196172T3 (da) 2006-06-19
US6465458B1 (en) 2002-10-15
DE60019473T2 (de) 2006-02-23
IL187513A0 (en) 2008-06-05
US20060142289A1 (en) 2006-06-29
SK286864B6 (sk) 2009-06-05
DE60022692T2 (de) 2006-06-22
EA200801806A1 (ru) 2008-12-30
KR20090087135A (ko) 2009-08-14
EA200400589A1 (ru) 2004-12-30
JP2003503450A (ja) 2003-01-28
SK286104B6 (sk) 2008-03-05
PT1632234E (pt) 2007-07-09
AU2004202096A1 (en) 2004-06-10
EA200801805A1 (ru) 2008-12-30
DE60035232D1 (de) 2007-07-26
KR100948757B1 (ko) 2010-03-23
US20080103145A1 (en) 2008-05-01
SK19382001A3 (sk) 2002-07-02
CA2375908A1 (en) 2001-01-11
DE60026627T2 (de) 2007-02-01
CL2008002868A1 (es) 2009-01-09
HK1049630A1 (en) 2003-05-23
US20020128173A1 (en) 2002-09-12
SK286667B6 (sk) 2009-03-05
HK1076723A1 (en) 2006-01-27
NO20016406L (no) 2002-02-19
US20030040464A1 (en) 2003-02-27
US20020086864A1 (en) 2002-07-04
US20040058925A1 (en) 2004-03-25
DE60019473D1 (de) 2005-05-19
BR0012136A (pt) 2002-06-11
PT1459751E (pt) 2005-11-30
US20020107249A1 (en) 2002-08-08
GEP20094798B (en) 2009-10-26
TW200607511A (en) 2006-03-01
AU771258B2 (en) 2004-03-18
TW200407146A (en) 2004-05-16
TW200607510A (en) 2006-03-01
DE60026704D1 (de) 2006-05-11
KR20020015363A (ko) 2002-02-27
ES2258251T3 (es) 2006-08-16

Similar Documents

Publication Publication Date Title
CN1660108A (zh) 高度选择性去甲肾上腺素再摄取抑制剂及其用途
CN1820754A (zh) 高度选择性去甲肾上腺素再摄取抑制剂及其用途
HK1089945A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
HK1076726A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
HK1076725A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
HK1076724A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
HK1076723B (en) Highly selective norepinephrine reuptake inhibitors and the use for the preparation of the medicament thereof
HK1049630B (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
HK1103019A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1076726

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1076726

Country of ref document: HK